dexfadrostat phosphate (DP13): Our Investigational Drug
An aldosterone synthase inhibitor, dexfadrostat phosphate (DP13) is a first-of-its-kind treatment for primary aldosteronism (PA) that medically targets the cause of the disease. DAMIAN successfully completed its Phase I Clinical Trial evaluating the pharmacological properties of dexfadrostat phosphate in healthy volunteers. The safety and efficacy of dexfadrostat phosphate was recently investigated across Europe in patients with PA in a Phase II Trial.
Currently available therapies have no impact on the cause of PA i.e., the overproduction of aldosterone. In contrast, dexfadrostat phosphate selectively inhibits the enzyme responsible for aldosterone production, thus directly reducing the amount of aldosterone in the body.